Laboratory and clinical variables of the patients treated with rituximab. B cell subsets were analyzed by flow cytometry. Results are shown as percentage of CD19+ lymphocytes.
| SJC | TJC | DAS28 | CRP, mg/dl | ESR, mm/h | CD27+IgD+, % | CD27+IgD–, % | CD27++ CD38+++, % | CD27–IgD+, % | |
|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | |||||||||
| Baseline | 9 | 10 | 4.84 | 0.56 | 12 | 15.5 | 14.0 | 2.5 | 67.5 |
| After RTX | 6 | 5 | 3.6 | 0.47 | 8 | 2.5 | 11.0 | 3.5 | 81.0 |
| Patient 2 | |||||||||
| Baseline | 15 | 11 | 5.80 | 8.71 | 33 | 12.0 | 16.5 | 2.7 | 63.0 |
| After RTX | 12 | 7 | 5.51 | 5.42 | 38 | 1.0 | 13.0 | 4.7 | 76.0 |
SJC: swollen joint count; TJC: tender joint count; DAS: Disease Activity Score; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.